These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

896 related articles for article (PubMed ID: 28508916)

  • 21. Considerations for Prescribing Target-Specific Oral Anticoagulants in the Setting of Renal Dysfunction or Drug Interactions.
    Pan EY; Sobieraj DM
    Conn Med; 2016 Feb; 80(2):105-11. PubMed ID: 27024982
    [No Abstract]   [Full Text] [Related]  

  • 22. Jurisdictional Guidance on DOAC Use-Will It Affect Practice? A Comparison of European, American, and Canadian Product Monographs.
    Lamb DA; Bungard TJ; Lowerison J; Semchuk WM; Thomson P; Brocklebank C; Bolt J
    Ann Pharmacother; 2020 Mar; 54(3):277-282. PubMed ID: 31529984
    [No Abstract]   [Full Text] [Related]  

  • 23. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR; Zhou L; Gellad WF; Lee JK; Slack MK; Martin JR; Lo-Ciganic WH
    Clin Ther; 2017 Jul; 39(7):1456-1478.e36. PubMed ID: 28668628
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis.
    van der Hulle T; Kooiman J; den Exter PL; Dekkers OM; Klok FA; Huisman MV
    J Thromb Haemost; 2014; 12(3):320-8. PubMed ID: 24330006
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Venous thromboembolism and cancer: Current and future role of direct-acting oral anticoagulants.
    Vedovati MC; Giustozzi M; Becattini C
    Thromb Res; 2019 May; 177():33-41. PubMed ID: 30849513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke.
    Kanai Y; Oguro H; Tahara N; Matsuda H; Takayoshi H; Mitaki S; Onoda K; Yamaguchi S
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):338-345. PubMed ID: 29033229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of oral anticoagulants for the extended treatment of venous thromboembolism using a mixed-treatment comparison, meta-analytic approach.
    Rollins BM; Silva MA; Donovan JL; Kanaan AO
    Clin Ther; 2014 Oct; 36(10):1454-64.e3. PubMed ID: 25092394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
    O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE
    Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An update on the bleeding risks associated with DOACs.
    Drug Ther Bull; 2017 Nov; 55(11):129-132. PubMed ID: 29117993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is it reasonable to use a lower DOACs dose in some patients with VTE? Yes.
    Imberti D; Mastroiacovo D
    Intern Emerg Med; 2017 Aug; 12(5):561-563. PubMed ID: 28647891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
    Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
    Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism.
    Mantha S; Ansell J
    J Thromb Thrombolysis; 2015 Feb; 39(2):155-65. PubMed ID: 24989022
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Challenges and Treatment for Stroke Prophylaxis in Patients with Atrial Fibrillation in Mexico: A Review.
    Alcocer L
    Am J Cardiovasc Drugs; 2016 Jun; 16(3):171-82. PubMed ID: 26923792
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of cancer-associated venous thromboembolism].
    Di Nisio M
    G Ital Cardiol (Rome); 2018 Sep; 19(9 Suppl 1):7S-12S. PubMed ID: 30284557
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New Oral Anticoagulants: What Prescribers Should Know; Differences and Similarities between Warfarin and "New Agents" (Dabigatran, Rivaroxaban, Apixaban, Edoxaban) - Review of Indications, Contraindications and Safety of Use.
    Petrasko M; Raizada A; Petraskova T
    S D Med; 2016 Aug; 69(8):363-369. PubMed ID: 28806005
    [No Abstract]   [Full Text] [Related]  

  • 36. Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: New Insights from Randomized Controlled Trials.
    Rojas-Hernandez CM; Oo TH
    Drugs; 2019 Apr; 79(6):621-631. PubMed ID: 30905033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Drug Treatment of Venous Thromboembolism in the Elderly.
    Boey JP; Gallus A
    Drugs Aging; 2016 Jul; 33(7):475-90. PubMed ID: 27255713
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Not Available].
    Själander S; Själander A
    Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512136
    [No Abstract]   [Full Text] [Related]  

  • 39. Safety ad efficacy of direct oral anticoagulants for extended treatment of venous thromboembolism.
    Imberti D; Pomero F; Benedetti R; Fenoglio L
    Intern Emerg Med; 2016 Oct; 11(7):895-900. PubMed ID: 27550399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct oral anticoagulants in the management of venous thromboembolism--evidence from major clinical trials.
    Holy EW; Beer JH
    Semin Hematol; 2014 Apr; 51(2):131-8. PubMed ID: 24861797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.